Pillar Biosciences, LC-SCRUM-Asia and LSI Medience Announce Liquid Biopsy Screening Collaboration in Lung Cancer

PartnershiponcoReveal® Essential+Positive

AI Analysis

Summary

Pillar Biosciences, LC-SCRUM-Asia, and LSI Medience announced a liquid biopsy screening collaboration with oncoReveal® Essential+ validated for cfDNA/cfRNA screening in the LC-SCRUM-Asia project, with testing planned to begin in August 2026.

Outcome Details

Liquid biopsy screening collaboration announced; oncoReveal® Essential+ validated at LSI Medience

Importance:6/10

Sentiment:

0.60

liquid biopsylung cancerscreeningcollaborationcfDNAcfRNAAsia-Pacific

Read the original article

Published by PR Newswire Biotech on August 19, 2026 2:00 PM

Read Original